Product Description
Autologous CD19-CD22 CAR-T cells. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04034446)
Mechanisms of Action: CAR-T,CD19,CD22
Novel Mechanism: Yes
Modality: CAR-T
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Juventas Cell Therapy
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Lymphoid Leukemia|B-Cell Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| B-ALL | P2 |
Not yet recruiting |
Lymphoma, B-Cell|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
2026-12-30 |
12% |
2025-02-08 |
|
| HY004102 | P2 |
Not yet recruiting |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2026-06-01 |
12% |
2025-02-08 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|